secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001104659-24-098059
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data
-------------------------------------------------------------------------------

- 81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.
- 46.2% confirmed CNS ORR (6/13) in patients with brain metastases at baseline.
- Median duration of response not reached; 90.9% (20/22) of confirmed responders remain on study.
- No Grade 4/5 TRAEs or treatment discontinuations due to TRAEs; safety consistent with prior data.
- Data presented at WCLC 2024; ArriVent plans virtual webinar on September 9, 2024 at 4:30pm ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924098059/0001104659-24-098059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924098059/tm2423588d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-098059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer